Literature DB >> 34921182

Functional and structural analysis of non-synonymous single nucleotide polymorphisms (nsSNPs) in the MYB oncoproteins associated with human cancer.

Shu Wen Lim1, Kennet JunKai Tan1, Osman Mohd Azuraidi2, Maran Sathiya3, Ee Chen Lim1, Kok Song Lai4, Wai-Sum Yap5, Nik Abd Rahman Nik Mohd Afizan6.   

Abstract

MYB proteins are highly conserved DNA-binding domains (DBD) and mutations in MYB oncoproteins have been reported to cause aberrant and augmented cancer progression. Identification of MYB molecular biomarkers predictive of cancer progression can be used for improving cancer management. To address this, a biomarker discovery pipeline was employed in investigating deleterious non-synonymous single nucleotide polymorphisms (nsSNPs) in predicting damaging and potential alterations on the properties of proteins. The nsSNP of the MYB family; MYB, MYBL1, and MYBL2 was extracted from the NCBI database. Five in silico tools (PROVEAN, SIFT, PolyPhen-2, SNPs&GO and PhD-SNP) were utilized to investigate the outcomes of nsSNPs. A total of 45 nsSNPs were predicted as high-risk and damaging, and were subjected to PMut and I-Mutant 2.0 for protein stability analysis. This resulted in 32 nsSNPs with decreased stability with a DDG score lower than - 0.5, indicating damaging effect. G111S, N183S, G122S, and S178C located within the helix-turn-helix (HTH) domain were predicted to be conserved, further posttranslational modifications and 3-D protein analysis indicated these nsSNPs to shift DNA-binding specificity of the protein thus altering the protein function. Findings from this study would help in the field of pharmacogenomic and cancer therapy towards better intervention and management of cancer.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34921182      PMCID: PMC8683427          DOI: 10.1038/s41598-021-03624-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

MYB oncoproteins; MYB, MYBL1, and MYBL2 plays important roles in the modulation of cell cycle, and dysregulation in these genes have been implicated with abberant behaviours of the tumour cells. The key functions of MYB proteins are mainly in cell growth and differentiation, thereof mutations within these genes are predicted to be a potential source for oncogenesis[1]. Numerous studies have reported mutation of MYB proteins toward pathogenesis of human cancers, especially acute lymphoblastic leukaemia (ALL)[2], paediatric low-grade gliomas[3], cancers of the gastrointestinal tract[4-6] and breast cancer[7].Growing evidences of MYB oncoproteins and cancers necessitates an in-depth understanding at molecular level in unravelling its pathogenesis towards cancer. The use of computational predictors to identify damaging non-synonymous single nucleotide polymorphisms (nsSNPs) towards understanding disease-causing role offers a time- and cost-effective alternative[8]. nsSNPs are changes in an amino acid that could disrupt the structure and stability of protein thus potentially increasing susceptibility towards certain disease[9,10]. Evaluating the influence of nsSNPs on the protein is important in determining its effect towards characterisation of the disease[11]. Recent studies employing computational approaches have also revealed the effectiveness of nsSNPs in understanding the molecular mechanisms of numerous diseases[12-14]. Considering the pathological role of MYB oncoproteins towards cancer, functional and structural analysis of MYB oncoproteins still remains vague. Therefore, this study sets to examine the role of nsSNPs of MYB, MYBL1, and MYBL2 genes through bioinformatics tools in understanding its pathogenesis toward cancer. This approach enables the differentiation of pathogenic mutations from an abundance of variations, narrowing down to highly significant variant for further investigation using laboratory validation[15]. In this study, MYB oncoproteins were subjected to multi-level functional and structural analysis in determining their pathogenicity. In brief, this involves (1) nsSNP analysis, where sequence evolutionary conservation information and structure-based information to determine damaging nsSNPs, (2) Prediction of protein stability, which evaluates the energetics of the folded and unfolded state of proteins in determining if the protein is stable, and (3) prediction of post-translational modifications. Each of these tools employs a different machine-learning algorithm to predict the outcomes.

Results

Retrieval of nsSNPs in MYB family genes

NCBI dbSNP was used to retrieve the SNPs of MYB oncoproteins. A total of 51,862 SNPs were extracted from the NCBI database of which; 13,632 of MYB, 17,770 of MYBL1, and 20,460 of MYBL2. Out of these SNPs, 1503 were nsSNPs.

Identification of deleterious nsSNPs in MYB family genes

The nsSNPs were then subjected to five different tools (PROVEAN, SIFT, Polyphen2, SNPs&GO and PhD-SNP) that has different prediction algorithms to identify nsSNP with significant deleterious effects which could affect the biological structure and the function of MYB proteins. Forty-eight nsSNPs were identified as “pathogenic” or “damaging” by all tools, hence classified at “high-risk” (Table 1).
Table 1

High risk nsSNPs identified in MYB family genes by in silico tools.

SNP IDAA changePROVEANSIFTPolyPhen-2SNPs&GOPhD-SNP
PredaScPredbScEffectcScPreddRIPredeRI
MYB
rs1302072057R73LDel− 3.80Dmg0Pro.dmg1Disease4Disease7
rs1302072057R73QDel− 6.65Dmg0Pro.dmg1Disease5Disease8
rs866246271C78YDel− 10.45Dmg0Pro.dmg0.999Disease7Disease9
rs1246761830K84EDel− 3.80Dmg0.001Pro.dmg0.998Disease5Disease4
rs1231582413P94RDel− 8.55Dmg0.001Pos.dmg0.608Disease3Disease1
rs1776412940W95LDel− 12.35Dmg0Pro.dmg1Disease4Disease7
rs1361650612G111SDel− 5.69Dmg0Pro.dmg1Disease5Disease7
rs1316378738A158EDel− 4.74Dmg0Pos.dmg0.577Disease7Disease6
rs1583273308R176QDel− 3.80Dmg0Pro.dmg1Disease6Disease8
rs1179275735N183SDel− 4.58Dmg0Pro.dmg1Disease7Disease5
rs1335964521R191QDel− 3.75Dmg0Pro.dmg1Disease2Disease5
rs1444007668K192EDel− 3.75Dmg0Pro.dmg0.999Disease7Disease6
rs1777011832D286YDel− 6.18Dmg0Pro.dmg1Disease4Disease7
rs1247338239W406CDel− 5.30Dmg0.001Pro.dmg0.985Disease0Disease5
rs1247579811P574SDel− 6.02Dmg0Pro.dmg1Disease0Disease5
rs775717051A594PDel− 3.37Dmg0.001Pro.dmg1Disease1Disease6
rs756830286G603SDel− 4.53Dmg0.007Pro.dmg1Disease0Disease5
MYBL1
rs1367098628R68CDel− 7.60Dmg0Pro.dmg1Disease3Disease7
rs767355502R68HDel− 4.75Dmg0Pro.dmg0.996Disease1Disease6
rs1472109411P83TDel− 7.60Dmg0Pos.dmg0.811Disease3Disease3
rs766676175G122SDel− 5.69Dmg0.002Pro.dmg0.975Disease3Disease5
rs768073245R156WDel− 6.55Dmg0.002Pro.dmg1Disease2Disease5
rs1299187617R160HDel− 4.74Dmg0Pro.dmg0.990Disease2Disease5
rs866260709S175YDel− 3.62Dmg0Pro.dmg1Disease0Disease2
rs1281804000R185QDel− 3.30Dmg0.003Pro.dmg0.978Disease0Disease3
rs1809689475E265KDel− 3.34Dmg0.005Pro.dmg0.957Disease2Disease6
rs1225867137M276TDel− 4.79Dmg0.006Pro.dmg0.992Disease2Disease6
rs1808814297P512RDel− 6.44Dmg0Pro.dmg1Disease1Disease6
rs1361362325C514WDel− 5.98Dmg0.002Pro.dmg1Disease1Disease6
rs770108773A562EDel− 3.54Dmg0.001Pro.dmg1Disease0Disease6
rs777095803A565PDel− 2.90Dmg0.003Pro.dmg1Disease1Disease7
rs777150665G596RDel− 3.07Dmg0.001Pro.dmg1Disease0Disease5
rs1281394929G721EDel− 5.73Dmg0.007Pro.dmg1Disease5Disease6
MYBL2
rs748449655L57RDel− 4.37Dmg0.001Pro.dmg0.999Disease8Disease2
rs1228232756R64CDel− 6.64Dmg0Pro.dmg1Disease8Disease5
rs867195152G102DDel− 6.10Dmg0Pro.dmg0.995Disease8Disease6
rs1164247754R116QDel− 3.35Dmg0.022Pro.dmg1Disease8Disease6
rs1323182096R124CDel− 7.06Dmg0Pro.dmg1Disease8Disease7
rs1300383239N127DDel− 4.52Dmg0.006Pro.dmg0.971Disease2Disease4
rs1295676923G166VDel− 8.00Dmg0Pos.dmg0.946Disease8Disease7
rs968286439R167KDel− 2.63Dmg0Pro.dmg0.999Disease7Disease5
rs1271670254D169GDel− 5.87Dmg0Pro.dmg1Disease7Disease7
rs1438994955S178CDel− 4.01Dmg0Pro.dmg1Disease3Disease3
rs781229138G188CDel− 6.21Dmg0.003Pro.dmg0.966Disease6Disease5
rs1171631148E552VDel− 5.52Dmg0.001Pro.dmg1Disease7Disease2
rs776972688G530RDel− 5.97Dmg0.001Pro.dmg1Disease7Disease2
rs779332836G669RDel− 6.13Dmg0Pro.dmg1Disease6Disease3
rs776117094R682WDel− 5.78Dmg0Pro.dmg1Disease5Disease1

AA amino acid, Pred prediction, TI tolerance index, Sc score, Del deleterious, Dmg damaging, Pro.dmg probably damaging, Pos.dmg possibly damaging, RI reliability index.

aPROVEAN: Del (Sc < − 2.5).

bSIFT: Dmg (Sc ≤ 0.05).

cPolyPhen-2: Pos.dmg (0.453 ≤ Sc ≤ 0.956), Pro.dmg (0.957 ≤ Sc ≤ 1.0).

dSNPs&GO: Disease (Probability > 0.5).

ePhD-SNP: Disease (Probability > 0.5).

High risk nsSNPs identified in MYB family genes by in silico tools. AA amino acid, Pred prediction, TI tolerance index, Sc score, Del deleterious, Dmg damaging, Pro.dmg probably damaging, Pos.dmg possibly damaging, RI reliability index. aPROVEAN: Del (Sc < − 2.5). bSIFT: Dmg (Sc ≤ 0.05). cPolyPhen-2: Pos.dmg (0.453 ≤ Sc ≤ 0.956), Pro.dmg (0.957 ≤ Sc ≤ 1.0). dSNPs&GO: Disease (Probability > 0.5). ePhD-SNP: Disease (Probability > 0.5).

Verification of high risk nsSNPs by PMut

The selected damaging nsSNPS were then submitted to PMut server to determine the probability score and the status of prediction of the resultant protein due to mutations. Table 2 shows the prediction scores and statuses. All MYBL2 nsSNPs were predicted as high-risk, whereas 16 nsSNPs and 14 nsSNPs from MYB and MYBL1 genes were also identified as “disease”. The “disease” status indicates that the mutated proteins are predicted to be pathogenic.
Table 2

Predictions of high risk nsSNPs in MYB oncoproteins by PMut, I-Mutant 2.0, and ConSurf.

ProteinnsSNP IDMutationPMutI-Mutant 2.0ConSurf
Score and percentagePredictionaStabilityRIDDG (kcal/mol)Conservation scorebPrediction
MYBrs1302072057R73L0.86 (91%)DiseaseDecrease9− 0.909Highly conserved and exposed (f)
rs1302072057R73Q0.73 (87%)DiseaseDecrease9− 1.389Highly conserved and exposed (f)
rs866246271C78Y0.79 (89%)DiseaseDecrease2− 0.079Highly conserved and buried (s)
rs1246761830K84E0.52 (79%)DiseaseDecrease1− 0.309Highly conserved and exposed (f)
rs1231582413P94R0.72 (86%)DiseaseDecrease7− 0.429Highly conserved and exposed (f)
rs1776412940W95L0.86 (91%)DiseaseDecrease7− 0.999Highly conserved and exposed (f)
rs1361650612G111S0.80 (89%)DiseaseDecrease9− 1.039Highly conserved and exposed (f)
rs1316378738A158E0.82 (90%)DiseaseDecrease7− 1.289Highly conserved and buried (s)
rs1583273308R176Q0.86 (91%)DiseaseDecrease8− 0.519Highly conserved and exposed (f)
rs1179275735N183S0.82 (90%)DiseaseDecrease4− 0.049Highly conserved and exposed (f)
rs1335964521R191Q0.77 (88%)DiseaseDecrease9− 1.139Highly conserved and exposed (f)
rs1444007668K192E0.55 (80%)DiseaseDecrease5− 0.959Highly conserved and exposed (f)
rs1777011832D286Y0.64 (84%)DiseaseIncrease20.112Exposed
rs1247338239W406C0.65 (84%)DiseaseDecrease6− 1.497Buried
rs1247579811P574S0.63 (84%)DiseaseDecrease9− 1.019Highly conserved and exposed (f)
rs775717051A594P0.65 (84%)DiseaseIncrease2− 1.019Highly conserved and buried (s)
rs756830286G603S0.50 (82%)NeutralDecrease6− 1.529Highly conserved and exposed (f)
MYBL1rs767355502R68C0.39 (86%)NeutralDecrease3− 0.739Highly conserved and exposed (f)
rs767355502R68H0.86 (91%)DiseaseDecrease7− 1.319Highly conserved and exposed (f)
rs1472109411P83T0.81 (89%)DiseaseDecrease40.089Highly conserved and exposed (f)
rs766676175G122S0.76 (88%)DiseaseDecrease7− 0.529Highly conserved and exposed (f)
rs768073245R156W0.82 (90%)DiseaseDecrease7− 1.049Highly conserved and exposed (f)
rs1299187617R160H0.77 (88%)DiseaseDecrease9− 1.179Highly conserved and exposed (f)
rs866260709S175Y0.76 (88%)DiseaseIncrease2− 0.649Highly conserved and buried (s)
rs1281804000R185Q0.67 (85%)DiseaseDecrease9− 1.444Highly conserved and exposed (f)
rs1809689475E265K0.63 (83%)DiseaseDecrease5− 0.386Exposed
rs1225867137M276T0.32 (89%)NeutralDecrease5− 0.629Exposed
rs1808814297P512R0.86 (91%)DiseaseDecrease9− 1.256Highly conserved and exposed (f)
rs1361362325C514W0.63 (84%)DiseaseDecrease5− 1.069Buried
rs770108773A562E0.78 (88%)DiseaseDecrease5− 0.769Highly conserved and buried (s)
rs777095803A565P0.53 (80%)DiseaseIncrease0− 1.858Highly conserved and exposed (f)
rs777150665G596R0.53 (80%)DiseaseDecrease7− 1.879Highly conserved and exposed (f)
rs1281394929G721E0.82 (90%)DiseaseIncrease2− 0.279Highly conserved and exposed (f)
MYBL2rs748449655L57R0.66 (85%)DiseaseDecrease6− 0.769Highly conserved and buried (s)
rs1228232756R64C0.78 (88%)DiseaseDecrease4− 0.669Highly conserved and exposed (f)
rs867195152G102D0.86 (91%)DiseaseDecrease5− 1.459Highly conserved and exposed (f
rs1164247754R116Q0.88 (92%)DiseaseDecrease70.139Highly conserved and exposed (f)
rs1323182096R124C0.89 (92%)DiseaseDecrease60.419Highly conserved and exposed (f)
rs1300383239N127D0.85 (91%)DiseaseDecrease6− 0.739Highly conserved and exposed (f)
rs1295676923G166V0.88 (92%)DiseaseIncrease0− 0.899Highly conserved and exposed (f)
rs968286439R167K0.87 (91%)DiseaseDecrease9− 0.989Highly conserved and exposed (f)
rs1271670254D169G0.79 (89%)DiseaseDecrease6− 1.049Highly conserved and exposed (f)
rs1438994955S178C0.53 (80%)DiseaseDecrease2− 1.339Highly conserved and exposed (f)
rs781229138G188C0.80 (89%)DiseaseDecrease8− 2.285Exposed
rs1171631148G530R0.76 (88%)DiseaseDecrease4− 1.699Highly conserved and exposed (f)
rs776972688E552V0.71 (86%)DiseaseIncrease20.089Highly conserved and exposed (f)
rs779332836G669R0.82 (90%)DiseaseDecrease7− 1.249Highly conserved and exposed (f)
rs776117094R682W0.82 (90%)DiseaseDecrease50.659Highly conserved and exposed (f)

RI reliability index, DDG free energy change value, (f) predicted functional residue (highly conserved and exposed), (s) predicted structural residue (highly conserved and buried).

aPMut: Disease (Score > 0.5), Neutral (Score ≤ 0.5).

bConSurf: highly variable (1), highly conserved (9).

Predictions of high risk nsSNPs in MYB oncoproteins by PMut, I-Mutant 2.0, and ConSurf. RI reliability index, DDG free energy change value, (f) predicted functional residue (highly conserved and exposed), (s) predicted structural residue (highly conserved and buried). aPMut: Disease (Score > 0.5), Neutral (Score ≤ 0.5). bConSurf: highly variable (1), highly conserved (9).

Determination of protein structural stability by I-Mutant 2.0

The structural stability of resultant proteins was predicted by I-Mutant 2.0. The output of I-Mutant 2.0 was expressed in free energy change value (DDG) and reliability index (RI). In total, 41 nsSNPs were confirmed to cause decrease in stability to the resultant proteins, however only 32 nsSNPs were predicted to have a DDG value < − 0.5, indicating its greater impact towards the proteins.

Evolutionary conservation analysis by ConSurf

The evolutionary conservation was determined through subjecting the mutated protein sequences to the ConSurf web server. A total of thirty-six nsSNPs of MYB family genes were identified as functional, highly conserved with exposed amino acid residues, whereas six nsSNPs were predicted as structural, highly conserved and buried. On the contrary, a total of four nsSNPs were predicted to be exposed but not functional, while two nsSNPs were predicted as buried and not functional (Table 2). The R73L, R73Q, K84E, P94R, W95L, G111S, R176Q, N183S, R191Q, K192E, P574S, R68H, P83T, G122S, R156W, R160H, R185Q, P512R, G596R, R64C, G102D, R116Q, R124C, N127D, R167K, D169G, S178C, G530R, G669R, and R682W mutations were predicted to be pathogenic, highly conserved and exposed with decreased protein stability, indicating the most significant damaging effect. Hence, these 30 high risk nsSNPs were proceeded with post-translational modification sites prediction.

Prediction of post-translational modification (PTM) sites

Post-translational modification (PTM) refers to the process where proteins undergo chemical modification to become functional and participate in respective cellular activities[16]. Putative methylation sites in the MYB family proteins and the 30 high risk nsSNPs were predicted using MusiteDeep and GPS-MSP 1.0. Only the wild-type R554 in MYBL1 was predicted as the common site (Fig. 1). Phosphorylation sites in the native and 30 mutated proteins were predicted using NetPhos 3.1 and GPS 5.0. NetPhos 3.1 predicted 268 residues in the three proteins to have phosphorylation potentials. A total of 386 residues in the proteins were found to be phosphorylated using the GPS 5.0, and 261 phosphorylation sites in all proteins were identified using both the tools, which consisted of 154 serines, 93 threonines, and 14 tyrosines (Fig. 1). However, only two wild-type reisudes (S175 and S178) and four mutant residues (S111, S183, S574, and S122) were the common sites present in the high risk nsSNPs. The ubiquitylation predictors employed in this study were BDM-PUB and UbiNet 2.0. BDM-PUB found 110 ubiquitylation sites at lysine residues in the family proteins. Whereas, only the wild-type K84 and K109 were predicted by UbiNet 2.0 in MYB. Both BDM-PUB and UbiNet 2.0 did not have common findings in all three proteins. After assembling the results from ConSurf and various PTM tools, a total of five high risk nsSNPs; G111S, N183S, P574S, G122S, and S178C containing putative phosphorylation sites were selected to proceed with comparative 3D modelling (Table 3).
Figure 1

Putative PTM sites and high risk nsSNPs in MYB family proteins. (a) MYB had 90 common phosphorylation sites (Ser:56, Thr:29, Tyr:5), of which 22 were functional sites. (b) MYBL1 had 1 common methylation site and 90 common phosphorylation sites (Ser:50, Thr:33, Tyr:7), of which 21 were functional sites. (c) MYBL2 had 81 common phosphorylation sites (Ser:48, Thr:31, Tyr:2), of which 24 were functional si.

Table 3

High risk nsSNPs selected by considering ConSurf and PTM predictions.

ProteinSNP IDMutationConSurfPTM
Conservation scoreaPrediction
MYBrs1361650612G111S9e, fPhosphorylation
rs1179275735N183S9e, fPhosphorylation
rs1247579811P574S9e, fPhosphorylation
MYBL1rs766676175G122S9e, fPhosphorylation
MYBL2rs1438994955S178C9e, fPhosphorylation

b buried residue, s predicted structural residue (highly conserved and buried), e exposed residue, f predicted functional residue (highly conserved and exposed).

aHighly variable (1), highly conserved (9).

Putative PTM sites and high risk nsSNPs in MYB family proteins. (a) MYB had 90 common phosphorylation sites (Ser:56, Thr:29, Tyr:5), of which 22 were functional sites. (b) MYBL1 had 1 common methylation site and 90 common phosphorylation sites (Ser:50, Thr:33, Tyr:7), of which 21 were functional sites. (c) MYBL2 had 81 common phosphorylation sites (Ser:48, Thr:31, Tyr:2), of which 24 were functional si. High risk nsSNPs selected by considering ConSurf and PTM predictions. b buried residue, s predicted structural residue (highly conserved and buried), e exposed residue, f predicted functional residue (highly conserved and exposed). aHighly variable (1), highly conserved (9).

Comparative modelling of wild-type MYB family proteins and their mutant structures

To investigate if the five high risk nsSNPs substantially alter the resultant proteins, predictive 3D modelling was performed along with the structural comparisons between wild-type and mutant models. The c1h88C and c1mseC templates were used to predict the wild-type MYB family proteins and their mutant models, excluding the P574S structure as this mutant residue was not covered in either template. TM-align revealed all mutant models had values of TM-score = 0 and RMSD = 1, showing no structural variations from their wild-type forms (Table 4). SWISS-MODEL was used to construct the 3D models for the wild-type proteins and their mutants. The best template used for the MYB family protein structures was 1h88.1.C as most 3D models can be generated based on this template. The generated mutant models were validated by ERRAT, and models with the highest possible GMQE scores, QMEAN Z-scores, and ERRAT values were selected for structural comparisons (Table 4). These models were visualised in Chimera 1.15 and the corresponding mutation positions induced by the nsSNPs were affirmed (Fig. 2). The structural integrity of generated wild-type and mutant protein structures were further validated with Ramachandran plot through the dihedral angles calculated.
Table 4

TM-score, RMSD value, GMQE score, QMEAN Z-score, ERRAT value, and PROCHECK Ramachandran plot analysis of the selected protein models.

ProteinModelTM-alignSWISS-MODELERRATPROCHECK Ramachandran plot analysis
TM-scoreaRMSDGMQE scoreQMEAN Z-scorebERRAT value (overall quality factor)cResidues in most favoured regionsdResidues in additional allowed regionsdResidues in generously allowed regionsdResidues in disallowed regionsd
MYB+NilNilNilNil97.222120 (87.6%)17 (12.4%)0 (0.0%)0 (0.0%)
G111S100.150.5599.3056122 (88.4%)15 (10.9%)0 (0.0%)1 (0.7%)
N183S100.160.7298.6111122 (89.1%)15 (10.9%)0 (0.0%)0 (0.0%)
MYBL1+NilNilNilNil97.9167123 (89.1%)15 (10.9%)0 (0.0%)0 (0.0%)
G122S100.15− 0.0298.6014123 (89.1%)15 (10.9%)0 (0.0%)0 (0.0%)
MYBL2+NilNilNilNil96.5278119 (86.2%)19 (13.8%)0 (0.0%)0 (0.0%)
S178C100.160.1996.5278118 (85.5%)20 (14.5%)0 (0.0%)0 (0.0%)

TM-score template modelling-score, RMSD root-mean-square deviation, GMQE global model quality estimation, QMEAN qualitative model energy analysis, “+” Wildtype.

aRandom structural similarity (0.0 < TM-score < 0.30), both structures are within the same fold (0.50 < TM-score < 1.00).

bLow quality model (QMEAN Z-score ≤ − 4.0).

cReliable model (ERRAT value > 85%).

dNumber of residues (percentage of residues).

Figure 2

Structural comparison of wild-type MYB family proteins with their mutant forms. (a) 3D model of wild-type MYB protein. (b) Superimposed structures of wild-type MYB protein and its mutant having mutation from Glycine to Serine at position 111. (c) Superimposed structures of wild-type MYB protein and its mutant having mutation from Asparagine to Serine at position 183. (d) 3D model of wild-type MYBL1 protein. (e) Superimposed structures of wild-type MYBL1 protein and its mutant having mutation from Glycine to Serine at position 122. (f) 3D model of wild-type MYBL2 protein. (g) Superimposed structures of wild-type MYBL2 protein and its mutant having mutation from Serine to Cysteine at position 178.This figure was generated using UCSF Chimera 1.15 (https://www.cgl.ucsf.edu/chimera/download.html).

TM-score, RMSD value, GMQE score, QMEAN Z-score, ERRAT value, and PROCHECK Ramachandran plot analysis of the selected protein models. TM-score template modelling-score, RMSD root-mean-square deviation, GMQE global model quality estimation, QMEAN qualitative model energy analysis, “+” Wildtype. aRandom structural similarity (0.0 < TM-score < 0.30), both structures are within the same fold (0.50 < TM-score < 1.00). bLow quality model (QMEAN Z-score ≤ − 4.0). cReliable model (ERRAT value > 85%). dNumber of residues (percentage of residues). Structural comparison of wild-type MYB family proteins with their mutant forms. (a) 3D model of wild-type MYB protein. (b) Superimposed structures of wild-type MYB protein and its mutant having mutation from Glycine to Serine at position 111. (c) Superimposed structures of wild-type MYB protein and its mutant having mutation from Asparagine to Serine at position 183. (d) 3D model of wild-type MYBL1 protein. (e) Superimposed structures of wild-type MYBL1 protein and its mutant having mutation from Glycine to Serine at position 122. (f) 3D model of wild-type MYBL2 protein. (g) Superimposed structures of wild-type MYBL2 protein and its mutant having mutation from Serine to Cysteine at position 178.This figure was generated using UCSF Chimera 1.15 (https://www.cgl.ucsf.edu/chimera/download.html). Wild-type and mutant PDB inputs were subjected to PROCHECK for analysis. The wildtype MYB has 120 residues (87.6%) in the most favored region, 17 residues (12.4%) in the additional allowed region. The more damaging mutants, G111S has 122 residues (88.4%) in the most favored region, 15 residues (10.9%) in the additional allowed region and 1 residue (0.7%) in the disallowed region, followed by N183S possesses 122 residues (89.1%) in the most favored region, 15 residues (10.9%) in the additional allowed region. In MYBL1, both G122S mutant and wildtype possess the same amino acid residue patterns, 123 residues (89.1%) in the most favoured region and 15 residues (10.9%) in the additional allowed region, indicating no significant changes in the alteration in the structure. Wildtype MYBL2 has 119 residues (86.2%) in the most favoured region and 19 residues (13.8%) in the additional allowed region. Mutant S178C in MYBL2 has 118 residues (85.5%) in the most favoured region and 20 residues (14.5%) in the additional allowed region as shown as in Table 4.

Discussion

This study has successfully identified high-risk pathogenic nsSNPs in the MYB oncoproteins towards understanding its association with human cancer using an in-silico approach. MYB oncoproteins play crucial roles in multiple signalling pathways for cellular activities. A study by Andersson and colleagues[17] showed that overexpressed wild-type MYB genes are normally benign, however, overexpression accompanied by gene alteration, dysregulated gene rearrangement or the incorrect oncoprotein binding onto enhancer region could promote tumorigenesis[1]. Despite the mutations in MYB oncoproteins being reported frequently in numerous cancers, the precise mechanisms of tumour initiations and/or maintenance remains vague. Therefore, examining the outcomes of deleterious nsSNPs of the MYB oncoproteins could potentially pave ways into a better understanding thus revealing its deleterious effects. Therefore, the aim of this study is to develop a bioinformatics pipeline in determining the most damaging nsSNPs and their effects on the structure and function of MYB, MYBL1, and MYBL2 proteins. A total of 51,862 SNPs were extracted from the NCBI dbSNP for the MYB family genes, of which 1503 were nsSNPs. Structural analysis using (PROVEAN, PolyPhen-2, SIFT, SNPs&GO, and PhD-SNP) and functional analysis using PMut resulted in 45 “high-risk” pathogenic nsSNPs. Next, the stability of these nsSNPs were determined using I-Mutant 2.0, where 41 nsSNPs were identified with “decreased stability”. Protein stability is one of the key features to determine if a protein is biologically active and functional[18]. Proteins with decreased stability due to mutation might give rise to tumorigenesis as the fitness level for normal proteins dropped and conferred the fitness for tumorigenic proteins[19]. Evolutionary conservation of MYB protein residues were calculated using ConSurf. The evolutionary conservation of an amino acid indicates its natural tendency for mutation to take place and highly conserved and exposed amino acids that undergo mutations can be expected to be most deleterious[20]. Thirty-six nsSNPs were identified to be highly conserved and exposed by ConSurf with the conservation score of 9. Next, these nsSNPs were subjected to PTMs analysis to determine its effect on regulating functions and structures of proteins. The G111S, N183S, P574S, G122S, and S178C showed to harbour putative phosphorylation sites. These nsSNPs coinciding with the putative phosphorylation sites may cause functional impairment and destabilisation of the corresponding proteins, thereby enhancing PTM impairment. PTM plays a pivotal role in modulating various protein functions and expressions, therefore mutations in PTM sites could lead towards malfunctions of the protein’ regulatory mechanisms, contributing to cellular dysfunctions such as transformation into cancer cells[21]. Several studies showed that mutated residues at phosphorylation sites had led to detrimental alterations in the expressions and functions of MYB[22,23] and MYBL2[24-26]. Among the four nsSNPs, G111S mutation in MYB was reportedly associated with uterine leiomyosarcomas[27]. Analysis using methylation and ubiquitylation predictors were also performed on the selected high risk nsSNPs. Only the R554 consensus methylation site was identified in MYBL1. As the results of methylation and ubiquitylation sites prediction were not in agreement for MYB and MYBL2, it was considered that both PTM sites were not predicted in these two proteins. Structural alterations on the resulting proteins were constructed using the Phyre2 homology modelling tool. Protein 3-dimensional analysis offers a detailed insight into the associated molecular changes[28]. Two templates (c1h88C and c1mseC) were utilised to construct the protein models. These templates were selected based on high sequence similarities and high GMQE value, providing a high coverage. The TM-scores and RMSD values obtained for the four mutants suggest that the nsSNPs might not have a significant structural consequence on the proteins for TM-align to detect. Protein structure homology-modelling tool SWISS-MODEL was conducted to remodel the four nsSNPs for structure and function prediction. The template (1h88.1.C) was used as it has high sequence identity and desired coverage range. GMQE scores of the models were estimated to be around 0.15–0.16, indicating that the models cover only 15–16% of the targeted sequence. All models have QMEAN Z-scores greater than − 4.0, indicating the high quality of the models. Finally, ERRAT evaluation gives overall quality factors that approximately hundred to all models, indicating high quality models were built. The G111S and G122S were identified to be located in the helix-turn-helix (HTH) myb-type 2 domain and S178C and N183S in the HTH myb-type 3 domain. These domains are important for the binding of DNA sequences and gene expression. This could cause activation and overexpression of the gene through loss of the C-terminal negative regulatory domain (C-myb)[29]. Previous studies have also reported that these could lead towards loss of the 3′ UTR binding sites thus negatively regulating MYB mRNA stability and translation[30,31]. Thus, the nsSNPs identified within these regions may have a complete shift in the DNA-binding specificity, resulting in a pathogenic protein synthesis[32].

Methods

Retrieving nsSNPs

nsSNPs of MYB (gene ID: 4602), MYBL1 (gene ID: 4603), and MYBL2 (gene ID: 4605) were extracted from NCBI (National Center for Biological Information) dbSNP database [https://www.ncbi.nlm.nih.gov/snp/][33]. DNA sequences as well as other information related to the nsSNPs of each gene, including the SNP IDs, allele changes, positions, protein accession numbers, residue changes, and global minor allele frequencies (MAFs) were also retrieved from this database. A total of 490 MYB, 483 MYBL1, and 530 MYBL2 nsSNPs were extracted respectively. The amino acid sequences of these genes (UniProtKB ID: P10242, P10243, and P10244) were obtained from the UniProtKB (Universal Protein Knowledgebase) database [https://www.uniprot.org/uniprot/] in FASTA format. Overview of the whole methodological approach is summarised in a schematic diagram (Fig. 3).
Figure 3

Diagrammatic representation of methodology.

Diagrammatic representation of methodology.

Identifying deleterious nsSNPs

The functional effect of the nsSNPs were predicted through five bioinformatics tools; PROVEAN (Protein Variation Effect Analyser) embedded with SIFT (Sorting Intolerant From Tolerant) [http://provean.jcvi.org/genome_submit_2.php?species=human][34-36], PolyPhen-2 (Polymorphism Phenotyping v2) [http://genetics.bwh.harvard.edu/pph2/bgi.shtml][37], and SNPs&GO (Single Nucleotide Polymorphisms and Gene Ontology) embedded with PhD-SNP (Predictor of human Deleterious Single Nucleotide Polymorphisms) [https://snps.biofold.org/snps-and-go/snps-and-go.html][38]. Those nsSNPs which were predicted to be deleterious by all five in silico tools were considered as “high-risk” nsSNPs and selected for further downstream analysis[39]. This ensured the stringency and accuracy of the results by incorporating the scores of all five computational tools to increase the precision of prediction.

Validating the high risk nsSNPs

PMut [http://mmb.irbbarcelona.org/PMut/] was resorted to validate the pathological nature of the selected high risk nsSNPs[40]. This neural network-based tool includes 27,203 harmful and 38,078 benign mutations for 12,141 proteins. Prediction score ranging from 0 to 1 was computed along with the prediction percentage. The nsSNPs with a score of ≤ 0.5 are classified as neutral, whereas those with > 0.5 are predicted as disease-associated[40].

Determining protein stability

Protein stability of the nsSNPs were determined through I-Mutant 2.0 [https://folding.biofold.org/i-mutant/i-mutant2.0.html][41]. This tool determines the increase decrease of stability change in mutated protein, and simultaneously estimates the corresponding values of free energy change (DDG). I-Mutant 2.0 uses a support vector machine method and a ProTherm-derived dataset, which is the most collective databank containing experimental thermodynamic data of free energy changes in mutated protein stability[41]. Along with these predictions, a reliability index (RI) ranging from 0 (lowest reliability) to 10 (highest reliability) was also computed by this web server.

Protein evolutionary conservation analysis

ConSurf [https://consurf.tau.ac.il/] was used to predict the evolutionary conservation of each residue position in the native MYB proteins[41]. The prediction is based on an empirical Bayesian algorithm and the phylogenetic relations between close homologous sequences. For each amino acid position, a colorimetric conservation score between 1 and 9 is calculated by the tool and then classified as either a variable (1–4), intermediately conserved (5–6), or highly conserved residue (7–9). The exposed (on protein surface) or buried (inside protein core) status of each residue position in the protein structure is also determined. A functional residue is predicted when it is highly conserved and exposed, whereas a structural residue is predicted if it is highly conserved and buried[20,42].

Post‑translational modification sites prediction

The putative methylation sites at arginine and lysine residues in each MYB protein, were predicted using MusiteDeep [https://www.musite.net/][43] and GPS-MSP 1.0 (Group-based Prediction System-Methyl-group Specific Predictor Version 1.0) [http://msp.biocuckoo.org/online.php][44]. Using a default cut-off of 0.5, the deep learning-based MusiteDeep predicts and labels the desired PTM sites in the sequence according to the confidence threshold[43]. As for GPS-MSP 1.0, types of mono, symmetrical di-, and asymmetrical di-methylation specific to arginines, as well as mono, di- and tri-methylation types specific for lysines were predicted [45]. Phosphorylation sites in each MYB protein at serines, threonines, and tyrosines were predicted using NetPhos 3.1 [https://services.healthtech.dtu.dk/service.php?NetPhos-3.1][46]. and GPS 5.0 (Group-based Prediction System Version 5.0) [http://gps.biocuckoo.cn/index.php][47]. A higher score in GPS 5.0 indicates higher probability of residues getting phosphorylated. Then, BDM-PUB (Prediction of Ubiquitination Sites with Bayesian Discriminant Method) [http://bdmpub.biocuckoo.org/prediction.php][48] and UbiNet 2.0 [https://awi.cuhk.edu.cn/~ubinet/index.php][49] were employed to predict putative protein ubiquitination sites at the lysines in MYB family proteins. A balanced cut-off option and a threshold of 0.3 were selected for the BDM-PUB server to perform the prediction based upon Bayesian Discriminant Method (BDM)[50].

Examining the effects of nsSNPs with 3D protein modelling

The nsSNPs that were predicted as pathogenic, highly conserved with decreased protein stability, and possessing PTM sites were chosen to proceed with 3D protein modelling using 1h88.1.C template. To construct the 3D structures for wild-type and mutants MYB proteins, two distinct homology-modelling tools were employed: Phyre2 (Protein Homology/analogy Recognition Engine V 2.0) [http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index][51] and SWISS-MODEL [https://swissmodel.expasy.org/][52]. Each nsSNP was individually substituted into the respective sequence of each MYB protein and then submitted to Phyre2 for the creation of 3D mutant models based on selected templates. TM-align (Template Modelling-align) [https://zhanggroup.org/TM-align/][53] was utilised to investigate the similarities between the modelled wild-type and mutant protein structures by computing template modelling-score (TM-score) and root-mean-square deviation (RMSD) values. TM-score yields a result from 0 to 1, where 1 denotes a perfect match between both structures[54]. Precisely, 0.0 < TM-score < 0.30 indicates random structural similarity, whereas 0.50 < TM-score < 1.00 implies that both structures are within the same fold[55,56]. A lower TM-score and a higher RMSD value indicate a greater structural deviation of mutant models from those of wild-type[57]. To build the 3D models in SWISS-MODEL, templates were analysed and selected based on coverage, sequence identity, qualitative model energy analysis (QMEAN) Z-score, and global model quality estimation (GMQE) score. A QMEAN Z-score of ≤ − 4.0 denotes a low quality model[58]. The GMQE score, which ranges from 0 to 1, indicates the likely accuracy of the model constructed with that alignment and the target coverage[59]. Therefore, templates with higher sequence similarities and a higher GMQE value were prioritized, concurrent with the coverage of the mutation site in that template, thus, template 1h88.1.C was selected. The built models were then validated by ERRAT [https://saves.mbi.ucla.edu/] and PROCHECK Ramachandran plot analysis [https://saves.mbi.ucla.edu/] to estimate their structural quality. Then, the validated structures were viewed and superimposed using Chimera 1.15 [https://www.cgl.ucsf.edu/chimera/download.html].

Conclusion

MYB family members are often aberrantly expressed in human cancers, suggesting that they could be important for tumour initiation and/or maintenance. In this study, a total of 30 nsSNPs were predicted as high-risk pathogenic, conserved with decreased stability, suggesting potential deleterious effect on the protein structure. Further PTM and 3D protein modeling indicated rs1361650612 (G111S), rs1179275735 (N183S), rs766676175 (G122S), and rs1438994955 (S178C) located within the helix-turn-helix (HTH) myb-type 2 and myb-type 3 domains were identified pathogenic with the ability to potentially cause great functional and stability impairment on the proteins. This study concise confidence that these findings could serve as a benchmark towards potential diagnostic and therapeutic interventions.
  54 in total

1.  Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches.

Authors:  Grace Shema Nzabonimpa; Henrik Berg Rasmussen; Søren Brunak; Olivier Taboureau
Journal:  Drug Metab Pers Ther       Date:  2016-02-19

2.  Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.

Authors:  Annika K Wefers; Damian Stichel; Daniel Schrimpf; Roland Coras; Mélanie Pages; Arnault Tauziède-Espariat; Pascale Varlet; Daniel Schwarz; Figen Söylemezoglu; Ute Pohl; José Pimentel; Jochen Meyer; Ekkehard Hewer; Anna Japp; Abhijit Joshi; David E Reuss; Annekathrin Reinhardt; Philipp Sievers; M Belén Casalini; Azadeh Ebrahimi; Kristin Huang; Christian Koelsche; Hu Liang Low; Olinda Rebelo; Dina Marnoto; Albert J Becker; Ori Staszewski; Michel Mittelbronn; Martin Hasselblatt; Jens Schittenhelm; Edmund Cheesman; Ricardo Santos de Oliveira; Rosane Gomes P Queiroz; Elvis Terci Valera; Volkmar H Hans; Andrey Korshunov; Adriana Olar; Keith L Ligon; Stefan M Pfister; Zane Jaunmuktane; Sebastian Brandner; Ruth G Tatevossian; David W Ellison; Thomas S Jacques; Mrinalini Honavar; Eleonora Aronica; Maria Thom; Felix Sahm; Andreas von Deimling; David T W Jones; Ingmar Blumcke; David Capper
Journal:  Acta Neuropathol       Date:  2019-09-28       Impact factor: 17.088

3.  Computational screening and molecular dynamics simulation of disease associated nsSNPs in CENP-E.

Authors:  Ambuj Kumar; Rituraj Purohit
Journal:  Mutat Res       Date:  2012-09-02       Impact factor: 2.433

4.  Drug resistance mechanism of PncA in Mycobacterium tuberculosis.

Authors:  Vidya Rajendran; Rao Sethumadhavan
Journal:  J Biomol Struct Dyn       Date:  2013-02-06

5.  c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development.

Authors:  You-Chin Lin; Ming-Wei Kuo; John Yu; Huan-Hsien Kuo; Ruey-Jen Lin; Wan-Lin Lo; Alice L Yu
Journal:  Mol Biol Evol       Date:  2008-07-29       Impact factor: 16.240

6.  Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.

Authors:  Benjamin B Williams; Meg Wall; Rebecca Yu Miao; Brenda Williams; Ivan Bertoncello; Michael H Kershaw; Theo Mantamadiotis; Michelle Haber; Murray D Norris; Anand Gautam; Phillip K Darcy; Robert G Ramsay
Journal:  Cancer Immunol Immunother       Date:  2008-04-03       Impact factor: 6.968

7.  ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids.

Authors:  Haim Ashkenazy; Elana Erez; Eric Martz; Tal Pupko; Nir Ben-Tal
Journal:  Nucleic Acids Res       Date:  2010-05-16       Impact factor: 16.971

8.  In silico prediction of splice-altering single nucleotide variants in the human genome.

Authors:  Xueqiu Jian; Eric Boerwinkle; Xiaoming Liu
Journal:  Nucleic Acids Res       Date:  2014-12-16       Impact factor: 16.971

9.  ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules.

Authors:  Haim Ashkenazy; Shiran Abadi; Eric Martz; Ofer Chay; Itay Mayrose; Tal Pupko; Nir Ben-Tal
Journal:  Nucleic Acids Res       Date:  2016-05-10       Impact factor: 16.971

10.  MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

Authors:  Pratiti Bandopadhayay; Lori A Ramkissoon; Payal Jain; Guillaume Bergthold; Jeremiah Wala; Rhamy Zeid; Steven E Schumacher; Laura Urbanski; Ryan O'Rourke; William J Gibson; Kristine Pelton; Shakti H Ramkissoon; Harry J Han; Yuankun Zhu; Namrata Choudhari; Amanda Silva; Katie Boucher; Rosemary E Henn; Yun Jee Kang; David Knoff; Brenton R Paolella; Adrianne Gladden-Young; Pascale Varlet; Melanie Pages; Peleg M Horowitz; Alexander Federation; Hayley Malkin; Adam A Tracy; Sara Seepo; Matthew Ducar; Paul Van Hummelen; Mariarita Santi; Anna Maria Buccoliero; Mirko Scagnet; Daniel C Bowers; Caterina Giannini; Stephanie Puget; Cynthia Hawkins; Uri Tabori; Almos Klekner; Laszlo Bognar; Peter C Burger; Charles Eberhart; Fausto J Rodriguez; D Ashley Hill; Sabine Mueller; Daphne A Haas-Kogan; Joanna J Phillips; Sandro Santagata; Charles D Stiles; James E Bradner; Nada Jabado; Alon Goren; Jacques Grill; Azra H Ligon; Liliana Goumnerova; Angela J Waanders; Phillip B Storm; Mark W Kieran; Keith L Ligon; Rameen Beroukhim; Adam C Resnick
Journal:  Nat Genet       Date:  2016-02-01       Impact factor: 38.330

View more
  2 in total

1.  In-Silico Analysis of Deleterious SNPs of FGF4 Gene and Their Impacts on Protein Structure, Function and Bladder Cancer Prognosis.

Authors:  Ee Chen Lim; Shu Wen Lim; Kenneth JunKai Tan; Maran Sathiya; Wan Hee Cheng; Kok-Song Lai; Jiun-Yan Loh; Wai-Sum Yap
Journal:  Life (Basel)       Date:  2022-07-09

2.  Expression pattern and clinical value of Key RNA methylation modification regulators in ischemic stroke.

Authors:  Xinyue Zhang; Yuanlin Wang; Beibei Dong; Yi Jiang; Dan Liu; Keliang Xie; Yonghao Yu
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.